Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease

What Was Tested

Researchers studied GHRH (Growth Hormone-Releasing Hormone) in the context of fatty liver & elevated liver enzymes in this randomized controlled trial publication.

This study used proteomics and gene set enrichment analysis to assess effects of a GH releasing hormone (GHRH) analog, tesamorelin, on circulating immune markers and liver tissue in people with human immunodeficiency virus (HIV) (PWH) and nonalcoholic fatty liver disease (NAFLD).

Why It Was Studied

The growth hormone (GH)/insulin-like growth factor-1 (IGF-1) axis modulates critical metabolic pathways; however, little is known regarding effects of augmenting pulsatile GH secretion on immune function in humans.

Who Took Part

Gene set enrichment analysis was performed on serial liver biopsies targeted to immune pathways.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this GHRH (Growth Hormone-Releasing Hormone) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind GHRH (Growth Hormone-Releasing Hormone) study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with GHRH (Growth Hormone-Releasing Hormone) could be set against what happens without it.

What Was Measured

Topics PubMed links to this paper include Biomarkers, Growth Hormone-Releasing Hormone, HIV Infections and Non-alcoholic Fatty Liver Disease.

The authors tagged it with the keywords HIV-infection, growth hormone releasing hormone, immune activation and nonalcoholic fatty liver disease.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of GHRH (Growth Hormone-Releasing Hormone) in people with fatty liver & elevated liver enzymes.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2021 (Clinical infectious diseases : an official publication of the Infectious Diseases Society of America), a journal based in United States.

More context: the GHRH (Growth Hormone-Releasing Hormone) compound page, Fatty liver & elevated liver enzymes research.